In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment?

Leukemia Research

Volumn 33, Issue SUPPL. 2, 2009, Pages

  Gore, Steven D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Azacitidine; Cancer epigenetics; DNA methyltransferase inhibitors; Histone deacetylase inhibitors; Myelodysplastic syndromes treatment; Predictors of response

Indexed keywords

4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA METHYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; CONTINUOUS INFUSION; DNA DAMAGE; DNA METHYLATION; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION; HUMAN; IN VITRO STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SKIN LYMPHOMA; T CELL LYMPHOMA; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; DNA DAMAGE; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 71149106051     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(09)70226-7     Document Type: Article

References (24)

1. Herman J.G., and Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349 (2003) 2042-2054
2. Fenton R.G., and Longo D.L. Cancer cell biology and angiogenesis. In: Kasper D.L., Braunwald E., Fauci A.S., Hauser S.L., Longo D.L., and Jameson J.L. (Eds). Harrison's Principles of Internal Medicine. 16th edition (2005), McGraw-Hill, New York 453-464
3. Esteller M. Epigenetics in cancer. N Engl J Med 358 (2008) 1148-1159
4. Jones P.A., and Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 3 (2002) 415-428
5. National Comprehensive Cancer Network. Myelodysplastic Syndromes. Version 2.2010. Clinical Practice Guidelines in Oncology. Available at: http://www.nccn.org Accessed October 9, 2009.
6. Fandy T.E., Herman J.G., Kerns P., Jiemjit A., Sugar E.A., Choi S.H., et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 114 (2009) 2764-2773
7. Figueroa M.E., Skrabanek L., Li Y., Jiemjit A., Fandy T.E., Paietta E., et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood (2009) 10.1182/blood-2009-01-200519
8. Figueroa M.E., Melnick A., and Greally J.M. Genome-wide determination of DNA methylation by Hpa II tiny fragment enrichment by ligation-mediated PCR (HELP) for the study of acute leukemias. Methods Mol Biol 538 (2009) 395-407
9. Dacogen® (decitabine for injection). Prescribing information (2008), SuperGen, Inc., Dublin, CA
10. Lu L.J., and Randerath K. Long term instability and molecular mechanism of 5-aza-cytidine-induced DNA hypomethylation in normal and neoplastic tissues in vivo. Mol Pharmacol 26 (1984) 594-603
11. Silverman L.R. Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). Oncologist 6 Suppl 5 (2001) 8-14
12. Silverman L.R., McKenzie D.R., Peterson B.L., Holland J.F., Backstrom J.T., Beach C.L., et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 24 (2006) 3895-3903
13. Kantarjian H., Issa J.P., Rosenfeld C.S., Bennett J.M., Arbitar M., DiPersio J., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 106 (2006) 1794-1803
14. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10 (2009) 223-232
15. Wijermans P., Suciu S., Baila L., Platzbecker U., Giagounidis A., Selleslag D., et al. Low dose decitabine versus best supportive care in elderly patients with Intermediate or High risk MDS not eligible for intensive chemotherapy: final results of the randomized phase III study (06011) of the EORTC Leukemia and German MDS Study Groups. Blood 112 (2008) Abstract 226.
16. Zolinza® (vorinostat capsules). Prescribing information (July 2008), Merck & Co., Inc., Whitehouse Station, NJ
17. Cameron E.E., Bachman K.E., Myöhänen S., Herman J.G., and Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21 (1999) 103-107
18. Herman J.G., Gore S.D., Mufti G.J., Fenaux P., Santini V., Silverman L.R., et al. Relationship among gene methylation, azacitidine treatment, and survival in patients with higher-risk myelodysplastic syndromes (MDS): results from the AZA-001 trial. AACR (2009) Abstract 4746.
19. Kantarjian H., Oki Y., Garcia-Manero G., Huang X., O'Brien S., Cortes J., et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109 (2007) 52-57
20. Gore S.D., Baylin S., Sugar E., Carraway H., Miller C.B., Carducci M., et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66 (2006) 6361-6369
21. Stresemann C., and Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 123 (2008) 8-13
22. Palii S.S., Van Emburgh B.O., Sankpal U.T., Brown K.D., and Robertson K.D. DNA methylation inhibitor 5-aza-2 -deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol 28 (2008) 752-771
23. Rosato R.R., Almenara J.A., Dai Y., and Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther 2 (2003) 1273-1284
24. Jiemjit A., Fandy T.E., Carraway H., Bailey K.A., Baylin S., Herman J.G., et al. p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage. Oncogene 27 (2008) 3615-3623